Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $105.00

Structure Therapeutics (NASDAQ:GPCR) had its price objective boosted by JPMorgan Chase & Co. from $65.00 to $105.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other brokerages also recently weighed in on GPCR. Guggenheim boosted their target price on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised their price target on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. The Goldman Sachs Group set a $102.00 price objective on shares of Structure Therapeutics in a report on Monday, January 19th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, HC Wainwright boosted their target price on shares of Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $104.45.

Structure Therapeutics Stock Down 1.6%

NASDAQ GPCR opened at $90.37 on Thursday. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90. The company has a 50 day moving average price of $60.89 and a 200 day moving average price of $36.64. The firm has a market cap of $5.48 billion, a PE ratio of -74.07 and a beta of -2.05.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, equities research analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC raised its holdings in shares of Structure Therapeutics by 6,550.0% during the second quarter. Signaturefd LLC now owns 6,650 shares of the company’s stock worth $138,000 after purchasing an additional 6,550 shares during the last quarter. Aberdeen Group plc lifted its holdings in shares of Structure Therapeutics by 61.4% in the 2nd quarter. Aberdeen Group plc now owns 401,624 shares of the company’s stock valued at $8,330,000 after buying an additional 152,725 shares during the period. Griffin Asset Management Inc. purchased a new stake in shares of Structure Therapeutics in the second quarter worth about $232,000. Allianz Asset Management GmbH acquired a new stake in Structure Therapeutics during the second quarter worth about $228,000. Finally, Pacific Heights Asset Management LLC purchased a new position in Structure Therapeutics during the second quarter valued at approximately $9,540,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.